DE112011102397T5 - Pharmazeutische Kombinationszusammensetzungen und Verfahren zur Behandlung von Schwindel, Kinetose und vegetativ-vaskulärer Dystonie - Google Patents

Pharmazeutische Kombinationszusammensetzungen und Verfahren zur Behandlung von Schwindel, Kinetose und vegetativ-vaskulärer Dystonie Download PDF

Info

Publication number
DE112011102397T5
DE112011102397T5 DE112011102397T DE112011102397T DE112011102397T5 DE 112011102397 T5 DE112011102397 T5 DE 112011102397T5 DE 112011102397 T DE112011102397 T DE 112011102397T DE 112011102397 T DE112011102397 T DE 112011102397T DE 112011102397 T5 DE112011102397 T5 DE 112011102397T5
Authority
DE
Germany
Prior art keywords
antibody
activated potentiated
synthase
potentiated form
test
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE112011102397T
Other languages
German (de)
English (en)
Inventor
Anmelder Gleich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44899157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE112011102397(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from RU2010130353/15A external-priority patent/RU2542445C2/ru
Priority claimed from RU2010130356/15A external-priority patent/RU2542453C2/ru
Priority claimed from RU2011127052/15A external-priority patent/RU2503462C2/ru
Priority claimed from RU2011127058/15A external-priority patent/RU2536232C2/ru
Application filed by Individual filed Critical Individual
Publication of DE112011102397T5 publication Critical patent/DE112011102397T5/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
DE112011102397T 2010-07-21 2011-07-15 Pharmazeutische Kombinationszusammensetzungen und Verfahren zur Behandlung von Schwindel, Kinetose und vegetativ-vaskulärer Dystonie Withdrawn DE112011102397T5 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
RU2010130353 2010-07-21
RU2010130353/15A RU2542445C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
RU2010130356 2010-07-21
RU2010130356/15A RU2542453C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство и способ лечения вегето-сосудистой дистонии, синдрома головокружения различного генеза и кинетозов
RU2011127052 2011-07-01
RU2011127052/15A RU2503462C2 (ru) 2011-07-01 2011-07-01 Способ лечения головокружения различного генеза, кинетозов и вегето-сосудистой дистонии (варианты) и лекарственное средство
RU2011127058 2011-07-01
RU2011127058/15A RU2536232C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
PCT/IB2011/002378 WO2012010974A2 (en) 2010-07-21 2011-07-15 Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia

Publications (1)

Publication Number Publication Date
DE112011102397T5 true DE112011102397T5 (de) 2013-05-08

Family

ID=44899157

Family Applications (1)

Application Number Title Priority Date Filing Date
DE112011102397T Withdrawn DE112011102397T5 (de) 2010-07-21 2011-07-15 Pharmazeutische Kombinationszusammensetzungen und Verfahren zur Behandlung von Schwindel, Kinetose und vegetativ-vaskulärer Dystonie

Country Status (23)

Country Link
US (1) US20130058981A1 (https=)
EP (1) EP2596018A2 (https=)
JP (2) JP2013536174A (https=)
KR (1) KR20130102542A (https=)
CN (1) CN103124741A (https=)
AR (1) AR082314A1 (https=)
AU (1) AU2011281248B2 (https=)
BR (1) BR112013001296A2 (https=)
CA (1) CA2805985A1 (https=)
CL (1) CL2013000201A1 (https=)
DE (1) DE112011102397T5 (https=)
EA (1) EA029998B1 (https=)
ES (1) ES2446643R1 (https=)
FR (1) FR2962910A1 (https=)
GB (1) GB2496342B (https=)
IL (1) IL224336A (https=)
IT (1) ITTO20110630A1 (https=)
MX (1) MX355371B (https=)
NZ (1) NZ606988A (https=)
PE (1) PE20131065A1 (https=)
PH (1) PH12013500141A1 (https=)
SG (2) SG187160A1 (https=)
WO (1) WO2012010974A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
EP2593474A2 (en) 2010-07-15 2013-05-22 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
EP2593477A2 (en) 2010-07-15 2013-05-22 Oleg Iliich Epshtein Pharmaceutical compositions and methods of treatment
PH12013500107A1 (en) * 2010-07-15 2013-03-11 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
KR20180127515A (ko) * 2010-07-21 2018-11-28 올레그 일리치 엡쉬테인 당뇨병 및 대사성 장애의 치료를 위한 제약학적 복합 조성물 및 방법들
EA029399B1 (ru) * 2010-07-21 2018-03-30 Олег Ильич ЭПШТЕЙН Комбинированная фармацевтическая композиция для лечения болезни альцгеймера и способ лечения болезни альцгеймера
EA029199B1 (ru) 2010-07-21 2018-02-28 Олег Ильич Эпштейн Комбинированная фармацевтическая композиция для лечения синдрома дефицита внимания и гиперактивности и способы лечения синдрома дефицита внимания и гиперактивности
PH12013500142A1 (en) 2010-07-21 2013-03-11 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
WO2012017328A2 (en) * 2010-08-06 2012-02-09 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
RU2113230C1 (ru) 1996-04-03 1998-06-20 Ильчиков Михаил Захарович Седативное лекарственное средство "авиаморе"
RU2156621C1 (ru) 1999-03-04 2000-09-27 Эпштейн Олег Ильич Нейротропное лекарственное средство
US7229648B2 (en) 2003-03-14 2007-06-12 Dreyer Lee R Homeopathic formulations useful for treating pain and/or inflammation
US7572441B2 (en) 2002-08-02 2009-08-11 Oleg Iliich Epshtein Media and method for treating pathological syndrome
US7582294B2 (en) 2002-08-02 2009-09-01 Oleg Oliich Epshtein Medicament for treating prostate diseases
US7700096B2 (en) 2002-08-02 2010-04-20 Oleg Iliich Epshtein Medicinal agent for treating erectile dysfunction

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150500A (en) * 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase
US5849528A (en) * 1997-08-21 1998-12-15 Incyte Pharmaceuticals, Inc.. Polynucleotides encoding a human S100 protein
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
AU2002258518A1 (en) * 2001-03-14 2002-09-24 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
RU2201255C1 (ru) * 2001-12-26 2003-03-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции сосудистого тонуса
AU2003295328A1 (en) * 2002-10-02 2004-04-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
PH12013500107A1 (en) * 2010-07-15 2013-03-11 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
EP2593474A2 (en) * 2010-07-15 2013-05-22 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
EP2593477A2 (en) * 2010-07-15 2013-05-22 Oleg Iliich Epshtein Pharmaceutical compositions and methods of treatment
EA029399B1 (ru) * 2010-07-21 2018-03-30 Олег Ильич ЭПШТЕЙН Комбинированная фармацевтическая композиция для лечения болезни альцгеймера и способ лечения болезни альцгеймера
US20120258146A1 (en) * 2010-07-21 2012-10-11 Oleg Iliich Epshtein Method of treating organic diseases of nervous system, pschoorganic syndrome and encephalopathy
EA029199B1 (ru) * 2010-07-21 2018-02-28 Олег Ильич Эпштейн Комбинированная фармацевтическая композиция для лечения синдрома дефицита внимания и гиперактивности и способы лечения синдрома дефицита внимания и гиперактивности
PH12013500142A1 (en) * 2010-07-21 2013-03-11 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
KR20180127515A (ko) * 2010-07-21 2018-11-28 올레그 일리치 엡쉬테인 당뇨병 및 대사성 장애의 치료를 위한 제약학적 복합 조성물 및 방법들

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
RU2113230C1 (ru) 1996-04-03 1998-06-20 Ильчиков Михаил Захарович Седативное лекарственное средство "авиаморе"
RU2156621C1 (ru) 1999-03-04 2000-09-27 Эпштейн Олег Ильич Нейротропное лекарственное средство
US7572441B2 (en) 2002-08-02 2009-08-11 Oleg Iliich Epshtein Media and method for treating pathological syndrome
US7582294B2 (en) 2002-08-02 2009-09-01 Oleg Oliich Epshtein Medicament for treating prostate diseases
US7700096B2 (en) 2002-08-02 2010-04-20 Oleg Iliich Epshtein Medicinal agent for treating erectile dysfunction
US7229648B2 (en) 2003-03-14 2007-06-12 Dreyer Lee R Homeopathic formulations useful for treating pain and/or inflammation

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
"International Task Force", bestehend aus der "European Society of Cardiology" und der "North American Society for Pacing and Electrophysiology", 1996
Doskin, et al., The Test Of differentiate Self-esteem Of Functional State, Psychological questions, 1973, Nr. 6, Seiten 141-145
G. M. Frimel, "Meditsyna", 1987, Seiten 9-33; "Hum. Antibodies. Monoclonal and recombinant antibodies, 30 years after" von E. Laffly, R. Sodoyer - 2005 - Band 14, - N 1-2, Seiten 33-55
Habib et al., Nitric Oxide Measurement From Blood To Lungs, Is There A Link? Pak. J. Physiol. 2007; 3(1)
M. B. Shtark, Brain-Specific Protein Antigens and Functions of Neuron, "Medicine", 1985; Seiten 12-14
M. V. Starostin, S. M. Sviridov, Neurospecific Protein S-100, Progress of Modern Biology, 1977, Band 5, Seiten 170-178
Markaryan et al., Vestibular selection by the method of continuous cumulative effect of accelerations by Coriolis, Military medical magazine, 1966, Nr. 9, Seiten 59-62
O. I. Epshtein, Antibodies to calcium-binding S100B protein block the conditioning of long-term sensitization in the terrestrial snail, Pharmacol. Biochem. Behav., 2009, 94(1):37-42
Quantitative evaluation of disorders of vestibular-vegetative sensibility, Cosmic biology and aeroastromedicine, 1981, Nr. 3, Seiten 72-75
T. A. Voronina et al., Kapitel 8, Antibodies to S-100 Protein in anxiety-depressive disorders in experimental and clinical conditions, in "Animal models in biological psychiatry", Hrsg. A. V. Kalueff N-Y, "Nova Science Publishers, Inc.", 2006, Seiten 137-152
Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart Rate Variability standards of measurement, physiological interpretation, and clinical use, Cir. 1996; 93:1043 1065
V. Castagne et al., Anti-bodies to S100 proteins have anxiolytic-like activity at ultra-low doses in the adult rat, J. Pharm. Pharmacol. 2008, 60(3):309-16
V. L. Karpman, et al., 1988; Novicov, et al., Study methods in physiology of military labour. Guidance, 1993, Seite 240
V. Schwabe "Homeopathic medicines", M., 1967, Seite 14-29
V. Shwabe "Homeopathic drugs", M., 1967, Seiten 14-29
Voyenizdat, Research Methodologies In Medical And Flight Inspection, 1972
Yardan et al., Usefulness of S100B Protein in Neurological Disorders, J. Pak. Med. Assoc. Vol. 61, Nr. 3, März 2011
Zheglov, et al., The Retention Of Performance Capability Of Sailing Personnel Of Navy. Guidance For Doctors, 1990, Seite 192

Also Published As

Publication number Publication date
GB2496342B (en) 2017-12-06
WO2012010974A3 (en) 2012-04-19
ITTO20110630A1 (it) 2012-01-22
PE20131065A1 (es) 2013-09-23
MX355371B (es) 2018-04-17
SG187160A1 (en) 2013-02-28
JP2013536174A (ja) 2013-09-19
AU2011281248B2 (en) 2017-02-02
ES2446643A2 (es) 2014-03-10
AU2011281248A1 (en) 2013-03-14
WO2012010974A8 (en) 2013-04-25
CN103124741A (zh) 2013-05-29
EP2596018A2 (en) 2013-05-29
SG10201505676RA (en) 2015-08-28
KR20130102542A (ko) 2013-09-17
ES2446643R1 (es) 2015-03-06
WO2012010974A2 (en) 2012-01-26
BR112013001296A2 (pt) 2017-12-19
CL2013000201A1 (es) 2015-01-23
MX2013000805A (es) 2013-10-28
GB201302925D0 (en) 2013-04-03
IL224336A (en) 2017-06-29
JP2016199571A (ja) 2016-12-01
FR2962910A1 (fr) 2012-01-27
US20130058981A1 (en) 2013-03-07
AR082314A1 (es) 2012-11-28
CA2805985A1 (en) 2012-01-26
GB2496342A (en) 2013-05-08
PH12013500141A1 (en) 2013-03-11
EA201300127A1 (ru) 2013-12-30
NZ606988A (en) 2015-08-28
EA029998B1 (ru) 2018-06-29

Similar Documents

Publication Publication Date Title
DE112011102397T5 (de) Pharmazeutische Kombinationszusammensetzungen und Verfahren zur Behandlung von Schwindel, Kinetose und vegetativ-vaskulärer Dystonie
DE112011102355T5 (de) Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von funktionellen Erkrankungen oder Zuständen des Gastrointestinaltraktes
DE112011102362T5 (de) Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Erkrankungen oder Zuständen, die mit neurodegenerativen Erkrankungen in Verbindung stehen
DE112011102349T5 (de) Pharmazeutische Zusammensetzung und Behandlungsverfahren
DE112011102411T5 (de) Verfahren zur Behandlung von Aufmerksamkeits-Mangel-Hyperaktivitäts-Störung
DE112011102409T5 (de) Verfahren zur Behandlung der Alzheimer-Krankheit
US20160251448A1 (en) Method of increasing the effect of an activated-potentiated form of an antibody
DE112011102412T5 (de) Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von mit Atemwegserkrankungen bzw. Atemwegsleiden assoziierten Erkrankungen bzw. Leiden
CN108685935B (zh) 一种含有腺苷受体激动试剂的食品
KR20140009110A (ko) 심혈관계와 연관된 질환 또는 장애를 치료하기 위한 복합 제약학적 조성물과 방법
RU2577137C2 (ru) Лекарственное средство для лечения кинетозов и способ лечения кинетозов
RU2577136C2 (ru) Лекарственное средство и способ лечения головокружений
AT396332B (de) Pharmazeutische zusammensetzung
RU2577130C2 (ru) Способ лечения вегето-сосудистой дистонии и лекарственное средство
RU2542453C2 (ru) Лекарственное средство и способ лечения вегето-сосудистой дистонии, синдрома головокружения различного генеза и кинетозов
UA112750C2 (uk) Комбінована фармацевтична композиція та методи лікування запаморочення, кінетозу та вегето-судинної дистонії
Manno Clinical investigations with marihuana and alcohol
Le Bars et al. Ginkgo biloba extract in cognitive disorders
Sorokhtin et al. The effect of anticholinesterase preparations on the dark adaptation of the eye
HOCH serious previous diseases. He had, however, a fall from the rigging of a boat three years before the onset of the present
Smart et al. ceutical Juurnal gives an account of some original investiga
Mochalova et al. The Effects of a Single Dose of Methylphenidate on Motor Performance in Young Healthy Participants Diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD)

Legal Events

Date Code Title Description
R012 Request for examination validly filed

Effective date: 20140509

R082 Change of representative

Representative=s name: DF-MP DOERRIES FRANK-MOLNIA & POHLMAN PATENTAN, DE

R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee